FFAR2 and metabolic disease: Euroscreen has furthermore patented a series of FFA2 antagonists for treatment or prevention of inflammatory, gastrointestinal and metabolic disorders, including 17, which was disclosed with IC50 = 10 nM in a calcium-based assay and 20 nM in a GTPγS assay (Figure 5).